Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.

Results 1 - 20 of 63 : 1 2 3 4 Next »

Recs

0
Member Avatar umight (48.96) Submitted: 9/19/2014 11:58:51 AM : Outperform Start Price: $77.02 ALNY Score: +1.07

They seem to have solved the delivery problem.From: http://www.technologyreview.com/featuredstory/530631/gene-silencing-drugs-finally-show-promise/

“The world went from believing RNAi would change everything to thinking it wouldn’t work, to now thinking it will,”

Recs

0
Member Avatar pchop12316 (86.37) Submitted: 9/15/2014 11:27:30 AM : Outperform Start Price: $70.96 ALNY Score: +8.58

great buyin point

Recs

0
Member Avatar Gclever88 (63.72) Submitted: 6/13/2014 5:10:47 PM : Outperform Start Price: $67.65 ALNY Score: +12.47

Drug pipeline looks good for 2015

Recs

0
Member Avatar simplemts (< 20) Submitted: 4/12/2014 8:15:30 PM : Underperform Start Price: $55.67 ALNY Score: -29.98

short-term red, lt green

Recs

0
Member Avatar TMFInnovator (55.37) Submitted: 4/10/2014 2:48:26 PM : Outperform Start Price: $58.51 ALNY Score: +23.75

Though biotech is certainly not my strong suit, I could see Alnylam being very successful in the coming years. The use of RNA interference to silence genetic diseases seems (to me, at least) to be an incredible medical discovery. Maybe that's why it won the 2006 Nobel Prize in medicine and Sanofi is investing so heavily in the company, valuing it at $80/share (http://www.bloomberg.com/news/2014-01-21/nobel-prize-winner-basis-of-sanofi-deal-for-rna-therapy.html).

Alnylam has a strong pipeline across all phases of development. I'm rooting for them to change the world of medicine. Outperform.

Recs

0
Member Avatar NHWeston102 (60.66) Submitted: 3/14/2014 12:14:35 PM : Outperform Start Price: $72.50 ALNY Score: -0.96

Overshadowed by the more publicity prominent ISIS Pharmaceuticals, ALNY is no less cutting edge in the RNAi arena. If Merck and Sanofy think so, I'll go along.

Recs

0
Member Avatar 1russianguy (70.71) Submitted: 3/4/2014 9:56:32 AM : Outperform Start Price: $81.67 ALNY Score: -11.96

BG long from $89.

Recs

7
Member Avatar zzlangerhans (99.78) Submitted: 1/17/2014 9:40:50 PM : Outperform Start Price: $96.14 ALNY Score: -28.95

What's the point of slaving away at these pitches on this dead, abandoned husk of a website? Because it's still the best way for me to look back and review my state of mind as I was making a prescient call, or in some cases making a stupid mistake. With Alnylam I can do both. Over six years of following this company I've switched from bear to bull, back to bear and now bull again. The only time I really had the situation pegged was in my first round of bullishness in 2010, when I recognized that despite RNAi being left for dead the pendulum was likely to swing back in its favor eventually. I squeezed a few thousand bucks out of bottom plays but never got the big score. Sadly, I let the continued depression of the segment erode my belief in Alnylam and switched to a bearish position just as the company was roaring back to life. I doggedly clung to my negativity on Alnylam until Portefeuille practically forced 100 shares down my throat after the big move had already passed.

As I mentioned in my active RXi pitch, Portefeuille called the coming RNAi explosion in early 2013 and emphasized stocks such as Tekmira, Arrowhead, Isis, and Alnylam for our zzporte collaborative portfolio. Having witnessed him rack up thousands of CAPS points on hepatitis C stocks in 2010 and 2011, it was hard to decline those picks even though some of them seemed to me to be the ugliest ducklings around. Sure enough, the frenzy exploded earlier this month when Genzyme/Sanofi bought 12% of Alnylam via a dilutive financing at 80, which injected 700M cash into Alnylam's coffers and only gave Genzyme the rights to Alnylam's RNAi pipeline outside of the US and Western Europe. Genzyme has an option to accumulate up to 30% of Alnylam, and I do expect them to go in that direction given what they were willing to pony up just for the third world rights. I uncharacteristically terminated my Alnylam red thumb at a huge loss and immediately moved into a green thumb in order to align my picks better with Portefeuille and zzporte. I've found that conquering my prejudices and inhibitons in the market might be painful in the short term, but when it means following Portefeuille the payoff is sweet.

Recs

0
Member Avatar Haugurafpeningum (32.84) Submitted: 1/14/2014 11:51:29 PM : Outperform Start Price: $88.89 ALNY Score: -21.53

zz 10

Recs

1
Member Avatar ChipNPutt11 (77.93) Submitted: 9/25/2013 4:31:15 PM : Outperform Start Price: $62.85 ALNY Score: +5.41

RNAi may we wave of applications, potential for new medications may lead to huge growth ... or get ALNY acquired. Hopefully they get to run with the insulation of their big partners, Could be breakthrough medical technology.

Recs

1
Member Avatar drb1000 (70.46) Submitted: 9/9/2013 12:31:48 PM : Outperform Start Price: $56.46 ALNY Score: +17.65

RNAi is a feasible gene regulating techology (unlike most of those touted in biotech).

Recs

1
Member Avatar d3ming (41.46) Submitted: 7/29/2013 8:10:45 PM : Outperform Start Price: $45.02 ALNY Score: +54.06

canslim filter

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:22:54 PM : Outperform Start Price: $44.75 ALNY Score: +55.58

Short. Biopharma. Revs down from $100m in 2010 to $66M 2012. Sold $93M of stock. Lots of insider selling.

Recs

1
Member Avatar SorrySam (74.64) Submitted: 2/23/2012 10:42:06 PM : Outperform Start Price: $12.93 ALNY Score: +454.90

Lots of buying by several insiders.

Recs

1
Member Avatar GoNuke (< 20) Submitted: 2/8/2012 7:28:58 PM : Outperform Start Price: $13.06 ALNY Score: +447.27

RNA interference is a very interesting and potentially powerful tool for gene therapy. It has proven very difficult to exploit; thus, all the major pharmaceutical companies have given up on pursuing development of RNAi based therapies -in house. ALNY is very good at keeping its "runway" long and healthy so it has been able to focus on developing this technology for some time. It manages to generate income from the "Majors" who do not want to be left out when RNAi technology is finally ready. This leaves ALNY as the nexus of RNAi technology. I expect that RNAi can be made to work and that ALNY will be the company that does it. As long as ALNY survives it has enormous potential; and yes I have some understanding of the phenomenon.

Recs

1
Member Avatar AllStarPortfolio (21.08) Submitted: 12/27/2010 10:01:12 AM : Outperform Start Price: $9.61 ALNY Score: +648.89

On December 23, 2010 portefeuille (99.94) wrote:

“Roche has elected to make a number of broad-based portfolio decisions across their entire R&D organization that appear to affect their ability for continued and sustained resource commitment to RNAi therapeutics,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “While we are disappointed and surprised to hear of their portfolio decision given the progress being made in the RNAi field, we remain more confident than ever in our efforts to advance RNAi therapeutics as a whole new class of innovative medicines to patients. In particular, we have achieved major breakthroughs in the safe and effective delivery of RNAi therapeutics and have also advanced our RNAi therapeutic efforts to patients in several clinical programs. We expect our delivery progress and clinical pipeline to continue to grow. Moreover, we believe we are on the frontier of demonstrating human proof-of-concept for these and other programs in the near term, and we are confident that these data will provide a strong foundation for continued execution on our business model and value creation strategy.”

http://finance.yahoo.com/news/Alnylam-Comments-on-Recent-bw-4192054651.html?x=0&.v=1

Recs

3
Member Avatar PDTBiotech (91.66) Submitted: 12/17/2010 8:58:32 AM : Underperform Start Price: $9.90 ALNY Score: -617.87

Alnylam has done an amazing job at keeping RNAi hyped as a legitimate technology, but the jig seems to be nearly up. Deal flow has been declining for a few years, marquis partners are starting to throw in the towel, and anyone who has ever worked with this technology in a lab is wondering how the hell anyone was able to get this far with something that is dirty even in a dish and can't be delivered.

Recs

0
Member Avatar rofgile (99.32) Submitted: 12/10/2010 12:22:06 AM : Underperform Start Price: $8.98 ALNY Score: -704.36

RNAi has been dumped by the major drug companies. I also personally think that RNA-interference is not a feasible drug technology in humans, and was just a bunch of early 2004-2006 buzz. Already not as important in biology labs as was predicted to be in 2004.

Recs

1
Member Avatar jlanganki (20.37) Submitted: 12/7/2010 11:30:07 PM : Outperform Start Price: $9.63 ALNY Score: +644.38

Priced at near cash on hand, with bright prospects in the coming years.

Recs

0
Member Avatar GoodSwimmer86 (< 20) Submitted: 12/6/2010 11:18:12 PM : Outperform Start Price: $9.47 ALNY Score: +657.78

Alnylam Pharmaceuticals is developing a new class of medicine called RNA Interface. The company is considered the leader in the technology, has an excellent R&D pipeline with clinical trials emerging, and an excellent balance sheet. As of Dec'10, the company's stock is valued at less than 1/3 of its 2008 value. The stock price depressed after news of one of its large partners pulling the plug on RNAi technology. The stock is very well priced because of investor fear and has excellent opportunity for growth.

Results 1 - 20 of 63 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement